A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Darinaparsin (Primary)
- Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors Solasia Pharma
- 08 Dec 2015 Pooled results (n=23) of this and other trial (see profile 223385) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 12 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.